Based on these associations, we hypothesise that high ACAA1 expression may indicate a tumour immune microenvironment more receptive to immune checkpoint blockade, positioning ACAA1 as a promising predictive biomarker for patient stratification. The gene discussed is ACAA1; the disease is neoplasm.